Article Text

other Versions


short report
Mutations in TMEM231 cause Meckel–Gruber syndrome
  1. Ranad Shaheen1,
  2. Shinu Ansari1,
  3. Elham AL Mardawi2,
  4. Muneera J Alshammari1,3,
  5. Fowzan S Alkuraya1,4
  1. 1Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
  2. 2Department of Obstetrics and Gynecology, Security Forces Hospital, Riyadh, Saudi Arabia
  3. 3Department of Pediatrics, King Khalid University Hospital and College of Medicine, King Saud University, Riyadh, Saudi Arabia
  4. 4Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
  1. Correspondence to Dr Fowzan S Alkuraya, Developmental Genetics Unit, King Faisal Specialist Hospital and Research Center, MBC-03 PO BOX 3354, Riyadh 11211, Saudi Arabia; falkuraya{at}


Background Meckel–Gruber syndrome (MKS) is a genetically heterogeneous severe ciliopathy characterised by early lethality, occipital encephalocele, polydactyly, and polycystic kidney disease.

Purpose To report genetic analysis results in two families in which all known MKS diseases genes have been excluded.

Methods In two consanguineous families with classical MKS in which autozygome-guided sequencing of previously reported MKS genes was negative, we performed exome sequencing followed by autozygome filtration.

Results We identified one novel splicing mutation in TMEM231, which led to complete degradation of the mutant transcript in one family, and a novel missense mutation in the other, both in the homozygous state.

Conclusions TMEM231 represents a novel MKS locus. The very recent identification of TMEM231 mutations in Joubert syndrome supports the growing appreciation of the overlap in the molecular pathogenesis between these two ciliopathies.

  • TMEM231
  • Joubert
  • Ciliopathy
  • Autozygome
  • Exome

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: and

Statistics from

Brief report

Ciliopathies are multiorgan system disorders caused by dysfunction of the primary cilium, a cytoskeletal appendage which plays essential roles in cellular homeostasis and organ development.1 ,2 Despite the common defective cilium complex, ciliopathies present diverse clinical features in addition to some overlapping phenotypes.1 ,3 The mechanism underlying the discordant clinical presentation of various ciliopathies has been poorly understood. Encouragingly, new revelations about cellular and developmental functions of ciliopathy associated genes have established an expanding network linking ciliopathies, cilium genes and their involvements in organ development, which provided an important stepping stone towards a better understanding of the genotype–phenotype correlation in these disorders.4 ,5

Meckel–Gruber syndrome (MKS) represents the severe end of the ciliopathy phenotypic spectrum. The disease is usually lethal shortly after birth, and affected children typically present with the triad of occipital encephalocele, polydactyly, and polycystic kidney disease, among other associated features.6 Twelve genes are known to cause this disorder when mutated: MKS1, TMEM216 (MKS2), TMEM67 (MKS3), CEP290 (MKS4), RPGRIP1L (MKS5), CC2D2A (MKS6), NPHP3 (MKS7), TCTN2 (MKS8), B9D1 (MKS9), B9D2 (MKS10), TMEM237, and C5orf42. Recently, we have suggested that mutations in EVC2 and EXOC4 may also cause MKS.7 In this study, we show that TMEM231 is the latest gene to be linked to MKS pathogenesis based on pathogenic mutations we identified in two families.

Family 1 consists of first cousin parents who lost two pregnancies because of MKS diagnosed prenatally; one was spontaneously aborted while the other was terminated (figure 1). The current pregnancy was complicated by oligohydramnios and was highly suspicious for MKS because of occipital encephalocele, polydactyly, and polycystic kidney. Therapeutic abortion was performed at the request of the parents. The family was enrolled under KFSHRC IRB approved protocol KFHSRC RAC#2080006 with written informed consent, and blood samples were collected from both parents and from the fetus before abortion. DNA was extracted followed by autozygome analysis essentially as described before.8 The only known MKS gene that was found to reside within the autozygome of the affected child was excluded by sequencing, so we proceeded with exome sequencing. Only one homozygous variant in TMEM231 (NM_001077416.1:c.751G>A) survived the filtration scheme shown in figure 1B. This variant affects the last nucleotide in exon 4 so we predicted that it affects the adjacent donor site. Unfortunately, this splicing variant could not be experimentally verified in the index because of the unavailability of RNA, so we tested blood-derived RNA collected in PAXGene tubes from the parents. No aberrant band was apparent in the parents on reverse transcriptase PCR (RT-PCR) using TMEM231 cDNA primers (figure 1C). However, upon sequencing the resulting amplicon, there was complete loss of heterozygosity for the c.751G>A variant at the level of RNA, suggesting complete nonsense mediated decay (NMD), most likely triggered by aberrant splicing and introduction of a premature stop codon. In order to investigate the nature of the aberrant transcript directly, we established lymphoblastoid cell lines from both parents. In contrast to RNA that was directly extracted from blood, RNA derived from the cell lines contained aberrant TMEM231 transcript in low abundance, as indicated by a faint smaller band on RT-PCR using the same primers as in the first RT-PCR experiment on blood-derived RNA (see online supplementary figure S1). Cloning experiments revealed that it in fact represents two aberrant transcripts, one in which the splicing mutation resulted in the retention of 47 bp from intron 4 (10% of colonies), and another that retained 11 bp from the same intron (5% of colonies) (the remaining 85% of colonies contained a normal transcript from the wild type allele). Both aberrant transcripts predict frameshift and premature truncation (p.Val251Serfs*21 and p.Val251Serfs*9) so they are the likely trigger of NMD we observed in blood.

Figure 1

(A) Pedigree of the Meckel–Gruber syndrome (MKS) family 1. The index is indicated by an asterisk. (B) Stacked Venn diagrams illustrating the number of exome variants that survived each filter as explained in the legend. For the final filter, variants were selected if they were expected to truncate the protein or, in the case of missense variants, if they were predicted to be pathogenic based on PolyPhen-2 and SIFT (Sorting Intolerant From Tolerant). (C) DNA chromatogram showing the novel missense splice site variant in the index of family 1 and parent with the site of mutation denoted by an asterisk. Reverse transcriptase PCR (RT-PCR) results for the TMEM231 missense splice site mutation using parent's blood-derived RNA as a template. Gel image showing the absence of an aberrant band, and the sequence chromatogram of the RT-PCR showing complete loss of heterozygosity for the c.751G>A variant at the level of RNA in the parent indicated by an asterisk. (D) AutoSNPa output for chromosome 16 revealing a block of shared homozygosity between the index family 1 and MKS_F18. The region is boxed in red. (E) Sequence chromatogram of the novel missense mutation identified in family 2 indicated by an asterisk, and multispecies alignment of orthologs. The affected glutamine residue (boxed in red) is conserved across species down to the zebrafish.

Interestingly, we observed a shared autozygous interval spanning 5.08 Mb between our patient and another patient who we described in our recent MKS case series as the only case in which exome sequencing failed to identify a causal mutation after applying the various filters (case MKS_F18 in Shaheen et al)7 (figure 1D). Re-examination of the exome variants from MKS_F18 in this interval revealed a heterozygous missense variant in TMEM231 (NM_001077416.1:c.902A>C) that had not been considered because it was heterozygous. However, Sanger sequencing showed that this variant is in fact homozygous, suggesting a technical error in the calling of this variant during exome sequencing. The affected residue is absolutely conserved across species (figure 1E) and is highly predicted to be pathogenic based on PolyPhen (0.992), SIFT (Sorting Intolerant From Tolerant) (0), and MutationTaster (0.999). Like the splicing mutation, this mutation was absent in 200 in house Saudi exomes. Thus, we suggest that both homozygous variants are pathogenic and likely to be disease-causing.

TMEM231 was recently identified as a protein that forms a complex with B9 and CC2D2A—two established MKS genes—at the transition zone of cilia, and that its deficiency at the cellular and organism level leads to ciliopathy.9 Very recently, compound heterozygosity for two mutations in TMEM231 was identified in three patients with Joubert syndrome.10 All three patients met the classical definition of Joubert syndrome as they had the constellation of oculomotor apraxia, molar tooth sign on brain MRI, breathing abnormalities, and developmental delay. While a subset of Joubert patients may have polydactyly and renal involvement like MKS, the clinical distinction between the two disorders is usually apparent. Thus, our finding of two pathogenic mutations in patients with classical MKS expands the list of genes that cause both disorders to also include TMEM231. Similar, as we have shown for TMEM237 and C5orf42, the correlation between the genotype of TMEM231 mutations and the resulting phenotype being Joubert syndrome or MKS remains undefined. It is unclear why the complete loss of function and missense mutations in TMEM231 found in our patients caused classical MKS while the compound heterozygous mutations in the same gene found in Srour's report resulted in Joubert syndrome.10 The consistent phenotype within a given family argues against stochastic factors during development. More likely, it appears that the phenotype is either allele-specific or at least genetic background-specific within a given family. Clearly, this will be the subject of future investigation once the cost of sequencing drops to a level that allows massive sequencing of entire cohorts of ciliopathy patients to assess for the contribution of modifiers.

In summary, we report the first MKS patients with TMEM231 mutations. This study, combined with the recent identification of TMEM231 mutations in Joubert syndrome, confirm the designation of TMEM231 as a ciliopathy gene with variable phenotypic consequences.


We thank the two families for their enthusiastic participation. We also thank the Genotyping and Sequencing Core Facilities at KFSHRC for their technical help. This work was supported by KACST grant 09-MED941-20 (FSA) and a DHFMR Collaborative Research Grant (FSA).


View Abstract

Review history and Supplementary material

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:


  • Contributors RS: collected and analysed data and wrote the manuscript. SA: collected and analysed data. EM: collected and analysed data. MJA: collected and analysed data. FSA: collected and analysed data and wrote the manuscript.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval KFSHRC IRB.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Open Access: This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.